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The monomer of the IgA class of antibodies resembles other immunoglobulins  in 
that  it consists of two  heavy (H) x chains and either two kappa or two  lambda light 
(L) chains. This H2L2 monomer is often further assembled and secreted as a  polymer 
of two or more monomers associated with a J  chain and joined together by disulfide 
bonds. Many species, including the mouse, express two structurally distinct allotypes 
of IgA. The covalent structure of one of these is similar to that of other immunoglob- 
ulin classes in that its H  chains are linked to each other and to its L chains by disulfide 
bonds (1). The other allotype, which represents all of the IgA expressed by BALB/c 
mice,  is  unique  among  normal  immunoglobulins  in  that  it  lacks  a  disulfide bond 
between its H  and L chains (2). This lack of an inter H-L disulfide bond must be due 
to  structural  differences  in  the  heavy  chain  because  the  same  light  chains  form 
disulfide bonds with other heavy chain classes (3). 
Potter  and  Kuff (4)  isolated BALB/c  myeloma tumors  that  synthesized unusual 
IgA  molecules.  The  H  chains  of six  such  tumors  were  significantly  smaller  than 
normal  alpha  chains  (5).  One  of them,  MOPC  47A  (47A),  has  been  completely 
sequenced, revealing a  precise deletion of its third constant region (CH3)  domain (6). 
In addition, 47A and the other five myeloma proteins were only partially assembled 
to form  H-L half-molecules (7, 8).  Perhaps the most  unusual  aspect of these variant 
immunoglobulins was that they all contained disulfide bonds between their H  and L 
chains  (7, 8).  Serologically similar proteins have been  detected in small amounts  in 
the intestinal contents of normal BALB/c mice (5). 
These  variant  IgA  proteins  are  interesting  not  only  because  of  their  unusual 
structure but also because of questions they raise about interdomain effects of deletions 
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in  one  part  of the  molecule  upon  the  structure  and  function  of other  parts  of the 
molecule. However, it has been difficult to directly address questions about the origin 
and function of these proteins due to the problem of establishing the geneology of in 
vivo tumors and because none of the variant immunoglobulins bound known antigens. 
These problems can be alleviated by using somatic cell genetic systems in which cells 
producing  variant  immunoglobulins  arise  at  high  frequency  in  vitro  from  cloned 
myeloma and hybridoma cell  lines of known antigen-binding  specificity  (9).  In this 
paper we report that variants with phenotypes and serological characteristics  similar 
to those of the IgA half-molecules  (a)  can rise spontaneously in culture  (b)  can have 
heavy chains of different  sizes,  and  (c)  can have the same affinity for hapten  as the 
parental  antibody  in  spite  of the  abnormal  H-L  disulfide  bond.  DNA  and  RNA 
studies suggest that these somatic variants arise through premature terminations that 
result  in C-terminal deletions. 
Materials  and Methods 
Cell Culture Condition and Detection of Variants.  The S107 cell line and the $1U9 variant were 
grown at 37°C in an atmosphere of 8% CO2 in Dulbeceo's modified Eagle's medium (DME) 
(Gibco H-21, Grand Island Biological Co., Grand Island, N. Y.) supplemented with  10% fetal 
calf serum (FCS, Flow Laboratories, Rockville, Md.), 5% NCTC 109 (Microbiological Associ- 
ates, Walkersville, Md.), streptomycin, and penicillin. The W3082 line and the T7 variant were 
grown in DME supplemented with 10% horse serum (Flow Laboratories). Cells were cloned in 
soft  agarose  over  rat  embryo  fibroblast  feeders,  overlaid  with  antigen,  and  variants  were 
identified  and  recovered  as  previously  described  (10-12).  Diazophenolphosphocholine was 
prepared as described by Chesbro and Metzger (13) and reacted with keyhole limpet hemocy- 
anin  (KLH)  (10).  Levan  was  prepared  by  differential  ethanol  precipitation  from  culture 
supernates of Leuconostoc mesenteroids NRRL B512 (14). 
Purification of S107 and $1U9 Proteins.  Approximately  107  cells  per  mouse  were  injected 
intraperitoneally  into Pristane-primed  BALB/c mice (15). After 7-10 d  the ascites  fluid was 
recovered. S 107 and S1U9 purification was achieved by affinity chromatography on a phospho- 
choline-Tyr-Gly-Sepharose 4B column. Bound material was eluted with 10 mM phosphocholine 
(PC) and subsequently dialyzed (16). A sample of purified 47A was generously provided by Dr. 
Fred Mushinski (National Cancer Institute). 
Labeling of Cells.  S107,  SaU9, W3028, and T7 cells were biosynthetically labeled in amino 
acid-depleted medium as previously described (17) except for the use of DME and  10% FCS. 
14  35  3  [  C]Lysine,  [  S]methionine,  and  [ H]tyrosine  (New  England  Nuclear,  Boston,  Mass.)  were 
used at 50,  50, and  100/~Ci/ml, respectively. Labeling in the presence of tunicamycin (Tm; 
generous gift of Dr. Robert Hamill, Eli Lilly and Co., Indianapolis, Ind.) was done similarly 
except that cells were preincubated for 1 h in growth medium containing 1.5/~g/ml Tm and 
labeled in medium also containing 1.5 #g/ml Tm. Cell lysates were prepared and immunopre- 
cipitated as described below. 
Lactoperoxidase-catalyzed  lZSI-surface labeling  was carried  out  by a  modification  of the 
technique described by Oi et  al.  (18).  Between 0.5  and  2  ×  107 cells were washed  twice in 
phosphate-buffered saline (PBS), r~suspended in 2 ml of PBS, and 0.5 mCi Na 125I (Amersham 
Corp., Arlington Heights, Ill.)  and 200 ~tg of lactoperoxidase (Sigma Chemical Co., St.  Louis, 
Mo.)  were added.  The reaction was started  by the addition  of 0.025  ml of 0.03%  hydrogen 
peroxide (H2Oz). Equal amounts of H20~ were added at 3, 6, and 9 min. At 10 min the reaction 
was stopped by washing the cells three times in cold PBS containing 50 #M potassium iodide. 
The cell pellet was then resuspended gently, lysed by the addition of 0.5 ml of 0.5% Nonidet P- 
40 (NP-40) in an isotonic buffer (0.01 M  Tris, 0.15 M  NaC1, and containing 8.5 ml  1 M  HCI 
and 0.305 g MgCI2-6H20 per liter), placed on ice for 20 min, and centrifuged for 10 min at 400 
g in order to pellet the nuclei. The supernatant  was recovered and saved for immunoprecipi- 
tation. 
Immunoprecipitation and Gel Electrophoresis.  To 0.5  ml of either cell  supernatant  ([14C]lysine 1556  MYELOMA  VARIANTS SYNTHESIZING IgA HALF-MOLECULES 
and [3H]tyrosine  labeling) or lysate (125I labeling) was  added 0.1  ml of a  25% suspension of 
rabbit anti-mouse IgA coupled to Sepharose 4B (19). The mixture was incubated overnight on 
a rotating mixer at 4°C. The Sepharose was then washed twice in cold PBS, once in 0.5% NP- 
40  (in the  same buffer as  above except  that  it  was  0.3  M  NaC1),  and  finally in a  buffer 
containing 10 mM phosphate buffer, pH 7.2, and 10 mM NaCI. Samples were eluted from the 
Sepharose by boiling for 1 min in 2% sodium dodeeyl sulfate (SDS). Samples to be reduced and 
alkylated were made 25 mM in dithiothreitol, incubated for 2 h at 37°C, and then made 50 
mM with recrystallized iodoacetamide, and incubated for  another 30  min at  37°C.  Before 
electrophoresis,  glyerol and phenol red were added to all samples at a final concentration of 10 
and 0.02%, respectively. 
Slab  gel  SDS-polyacrylamide gel  electrophoresis  (PAGE),  using either the  phosphate or 
discontinous Tris-glycine buffer system, was done as described by Maizel (20). Depending on 
the size resolution desired, final polyacrylamide concentrations of 5%, 7.5%, or 10% were used. 
Serology.  Monoclonal anti-IgA  constant region and anti-T  15 Variable region antibodies were 
kindly provided by Angela Giusti (Albert Einstein College of Medicine). Rabbit anti-mouse 
IgA Fc was prepared by repeatedly injecting rabbits with 1 mg ofIgA Fc fragment prepared by 
papain digestion of the  myeloma protein  W3129  in  complete  Freund's adjuvant. Double 
diffusion (Ouchterlony) analysis was done as described (21). Inhibition of hemagglutination 
assays were carried out by a modification of the method of Evans et al. (22). Affinity-purified 
S107 protien was attached to sheep erythrocytes (SRBC, 3 mg protein/0.5 ml packed cells in 
10 ml PBS) by treatment for 30-60 min with glutaraldehyde (Sigma Chemical Co.) at a final 
concentration of 0.25%. The titer of the various hemagglutinating antibodies was determined 
by reacting them with S107-SRBC in PBS containing 1% bovine serum albumin (BSA).  A 
fourfold excess of antibody was then incubated with dilutions of S107 or variant protein and 
S107-SRBC to determine the ability of these proteins to inhibit hemagglutination. 
Anti-PC binding site antiserum was prepared according to Claflin and Davie (23). Solid- 
phase radioimmunoassay (RIA) using this serum was performed as has been described (10). 
The only modification was that the incubation  with labeled S107 and inhibitor was carried out 
for 3 h rather than overnight. RIA with monoclonal antibodies were done similarly except that 
the wells were coated with 0.05 ml of the respective affinity-purified monoclonal antibody (3 
#g/ml) instead of with the antibinding  site antiserum. 
Equilibrium Dialysis.  Equilibrium dialysis was done by the steady-state, flow dialysis method 
of Colowiek and Womack (24). The flow rate used was 3.0 ml/min. The upper chamber of 1.5 
ml contained 5.5 mg of SxU9 protein and 3.75  ×  10  -9 mol of [14C]PC (55 mCi/mmol, New 
England Nuclear). In order to drive off increasing amounts of the [X4C]PC, successive 0.015-ml 
aliquots of 6.25 ×  10  -4 M PC solution were added. 
Carboxypeptidase A and B Digestions.  C-terminal analysis was done by a modification of the 
procedure described by Kehry et al.  (25). Phenylmethylsulfonylfluoride-treated  carboxypepti- 
dase  A  (Sigma  Chemical  Co.)  was  prepared  by  method  ii  as  described  by  Ambler  (26). 
Phenyimethylsulfonylfluoride-treated  carboxypeptidase B  (Worthington Biochemical Corp., 
Freehold, N. J.) was thawed and diluted 1:10 in 0.1 M ammonium bicarbonate  just before use. 
Digestions were  done in 0.1  M  ammonium bicarbonate, 0.1% SDS  at  a  molar enzyme to 
substrate ratio of 1:40. Each 0.25-ml sample contained 130,000-250,000  cpm of reduced and 
alkylated (as for SDS-PAGE) [3H]tyrosine-labeled parent or variant protein and 0.25  mg of 
carrier rabbit IgG (Pentex Biochemical, Kankakee, Ill.). Incubations  were done at 37°C for 2.5, 
5,  15, 40, and 90 min. Substrate controls that received enzyme boiled in 0.1 M acetic acid for 
15 min were incubated for 90 min. All reactions were stopped by the addition of equal volumes 
of 40% trichloroacetic acid (TCA), placed on ice for 20 min, centrifuged at 400 g for  10 min, 
and then an aliquot of each supernatant was counted. Substrate controls were subtracted from 
each time point. Mole tyrosine released per mole protein was calculated by multiplying the 
ratio of released  supernatant cpm to initial TCA precipitable cpm by the number of tyrosine 
residues present. Assuming an equimolar ratio of H and L, S107 protein contains 30 tyrosine 
residues (27-29 and P. Tucker, personal communication). Because  the complete sequence of 
W3082 antibody has not been determined, it was also assumed to contain 30 tyrosine residues. 
$1U9 and T7 protein were estimated to contain 27 and 26 residues,  respectively, based on the 
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DNA Isolation and Gel Analysis.  High molecular weight DNA was isolated from the myeloma 
cells essentially as described by Wigler et al.  (30) except that lysates were treated with RNase 
(50/~g/ml,  30  rain  at  37°C)  before pronase  treatment.  DNA was digested  with  restriction 
enzymes as directed by the supplier (Bio-Rad Laboratories, Richmond, Calif., or New England 
Biolabs,  Beverly, Mass.).  10/~g of DNA was applied per lane of a Tris-borate (31) agarose gel. 
Molecular  hybridizations were  done by standard  procedures  (30)  except  that  10%  dextran 
sulfate was added to the hybridization. The n2p nick-translated DNA probe (32) was prepared 
using  the  1.6  kilobase  (kb)  Eco  R1-Sma  1 fragment  isolated  from a  recombinant  plasmid 
containing the 4.4 kb Eco R1 fragment of the alpha gene. The plasmid was the generous gift 
of Dr. S. P. Kwan (Albert Einstein College of Medicine). 
RNA Isolation and Gel Analysis.  Myeloma cells were washed in PBS (0.15 M  NaCI, 0.01  M 
sodium phosphate, pH 7.6), resuspended  in 20 mM Tris, 2 mM Ca  ++, 2 mM Mg  ++, pH 8.3, 
and lysed with 0.5% NP-40. Nuclei were removed by centrifugation, SDS, NaCI, and EDTA 
added to 0.5%, 0.25  M, and  10 mM, respectively, and the cytoplasmic lysates extracted three 
times with 90% phenol. The RNA was then precipitated with ethanol. Total cytoplasmic RNA 
was fractionated by eleetrophoresis on agrose gels containing 2.2 M  formaldehyde, 20 mM 3- 
(4-morpholino)propanesulfonic acids (MOPS),  5 mM sodium acetate, and 5/~g/ml ethidium 
bromide.  Samples were prepared  by resuspending  RNA in 50% formamide  (ultrapure  from 
Bethesda  Research  Laboratories,  Rockville,  Md.),  2.2  M  formaldehyde and  MOPS/sodium 
acetate/EDTA, as above, heated at 60°C for 5 min, quickly chilled on ice, and applied to the 
agarose gel after the addition of Ficoll-bromophenol blue. Electrophoresis was carried out at 
100 V in the cold with buffer circulation for ~ 18 h. RNA markers were visualized by ultraviolet 
light. RNA was blotted to nitrocellulose as described by Thomas (33). 
In  Vitro Translation.  Ethanol-precipitated RNA was resuspended in 400 mM NaC1,  10 mM 
Tris 1 mM EDTA, 0.2% SDS, pH7.5, and bound to oligo-dT-eellulose (Collaborative Research 
Inc., Waltham,  Mass.).  The column was washed  with  100 mM  NaCI,  10 mM Tris,  1 mM 
EDTA, 0.2% SDS, pH 7.5, and the bound poly A+ mRNA eluted with  10 mM Tris,  1 mM 
EDTA, and 0.2% SDS, pH 7.5. NaCI was added to 0.3 M and the RNA precipitated with 2 vol 
of ETOH at -20°C. 
In vitro translation was done using a rabbit reticuloeyte lysate and [SSS]methionine  (1,370 
Ci/mmol, Amersham Corp.). A mix of 80% lysate and 20% labeled amino acid was prepared. 
mRNA (400 ng) was added in 1-10 pl of the assay mix, and the reaction mixture incubated 90 
s at  30°C. It was then diluted with  200/~1 of PBS, and  1 /.tl of rabbit  anti-mouse alpha and 
kappa were added. Immune complexes were precipitated with Staph A essentially as described 
by Kessler (34). 
Results 
Isolation of Variants.  In an effort to identify variant mouse myeloma cells producing 
antibodies that no longer bound antigen, the S 107 and W3082 cultured myeloma cell 
lines were cloned in soft agarose and overlaid with their respective antigens  (10,  12). 
Both S107 and W3082 produce IgA, kappa antibodies  (35, 36). S107 reacts with the 
hapten  PC and was overlaid with PC attached to the protein carrier KLH, whereas 
W3082  was  overlaid  with  levan.  Most  of the  clones  secreted  polymers  of IgA that 
reacted with the antigen in the agarose to form an antigen-antibody precipitate visible 
around the myeloma colonies. Approximately  1% of the clones were not surrounded 
by such a precipitate and a  number of these were recovered from the agar, expanded 
to mass culture,  and examined  in  more detail.  Some of these  spontaneous  variants 
produced superficially normal IgA antibodies that bound to antigen less well than the 
parental  myeloma proteins, whereas others had simply lost their ability to synthesize 
or secrete detectable amounts of IgA. However, one of the S 107 variants, called $1U9, 
and one of the W3082 variants, called T7, secreted structurally altered immunoglob- 
ulins.  Because  both  of these  spontaneous  somatic  variants  resembled  the  variant 1558  MYELOMA VARIANTS SYNTHESIZING IgA HALF-MOLECULES 
tumors originally described by Potter and  Kuff (4),  the variants and  their parental 
myelomas were examined in more detail. 
Polypeptide Size and Covalence Structure of the Variants.  Fig.  1 compares the electropho- 
retic migration on SDS-PAGE of the immunoglobulins secreted by the W3082  and 
S107  parents, and  their respective T7  and  SaU9  variants.  As can be seen in  lanes a 
and d, in the absence of reducing agents, SDS dissociates the parental proteins into 
H  chain polymers (H2 and Hn), L chain dimers, and free L chains. This demonstrates 
that the IgA produced by W3082 and S107 resemble normal BALB/c IgA in lacking 
inter-H-L disulfide bonds.  Reduction  converts the  H2 and  Hn polymers into  free H 
chains, thus showing the presence of inter-H chain disulfide bonds  (Fig.  1, compare 
lanes a and d with e and h). The variants display a strikingly different pattern. In the 
absence of reducing agents, each of the variant proteins exhibits a  major band whose 
mobility is intermediate between that of parental  H2 and  L2 (Fig.  1, lanes b  and c). 
When the variant proteins are reduced in the presence of SDS, two major bands are 
generated, one of which comigrates with parental  L  chains while the other migrates 
more rapidly than the parental H  chains  (Fig.  1, lanes f and g). This electrophoretic 
behavior, similar to  that  described  for the  in  vivo generated  half-molecules such as 
47A  (5),  indicates  that  both the  $1U9  and  T7  immunoglobulins contain  a  small  H 
chain. Furthermore, it suggests that although the variant H  chains do not form inter- 
H  chain  disulfide bonds,  most of them do form an aberrant  H-L chain  bond.  This 
was confirmed by recovery experiments  (data  not  shown).  It  should  be mentioned 
that  the  H  chains  of T7  and  47A comigrate exactly on  both  phosphate  and  Tris- 
glycine SDS gels (data not shown). 
To determine whether  the  size differences among the  $1U9,  T7,  and  parental  H 
chains were due  to primary amino acid changes or to glycosylation differences, the 
various proteins were radioactively labeled in the presence or absence of Tm, which 
inhibits glycosylation by preventing the addition of the core sugars (37).  Fig. 2, lanes 
a, c, f, and h  show the proteins labeled without the drug, whereas lanes b, d, e, and 
Fla.  I.  SDS-PAGE  of immune precipitated secretions of $107, StUg, W3082, and T7. Cells were 
labeled with [14C]lysine, secretions immune precipitated, and  run  on a  7.5% phosphate gel  as 
described in  Materials and  Methods. Samples in  lanes e-h were reduced and alkylated, while 
samples in lanes a-d were untreated. Samples  are as follows: a and e, SI07; b and f, SjUg; c and g, 
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Fro.  2.  Size  comparison of SIU9 and  T7 proteins with Tm-treated  cells and cell-free synthesis. 
Cells were either treated with 1.5 pg/ml Tm or left untreated, labeled with [3SS]methionine, lysed 
with  0.5% NP-40, and  immune  precipitated  as described in  Materials  and  Methods. Cell-free 
synthesis in a rabbit reticulocyte system was also carried out as described. SDS-PAGE was done on 
a 7.5% phosphate gel. Samples b, d, e, and g were from Tm-treated  cells, while a, c, f, and h were 
from untreated cells. Samples are as follows: a and b, St07; c and d, SIUa; e and f, T7; g and h, 
W3082; i, in vitro synthesized SlUg;  j, in vitro synthesized T7, 
g  show the proteins  labeled  in the presence of the drug. The difference in mobilities 
of the  unglycosylated  $1U9  and  T7  H  chains  (lanes  d  and  e)  shows  that  their  size 
difference  is  not  due  to  carbohydrate  differences.  Similarly,  comparison  of lanes  d 
and  e  with  b  and  g  shows  that  the  size  difference  between  the  variants  and  their 
respective parents is also not due solely to an alteration  in carbohydrate structure.  In 
vitro  synthesis  of  $1U9  and  T7  protein  utilizing  poly  A +  mRNA  and  a  rabbit 
reticulocyte  system  (lanes  i  and j)  confirms  the  polypeptide  deletions.  Comparison 
with  the  in  vitro  products  of the  parental  cell  lines  (data  not  shown)  demonstrates 
that  the deletions are not due to in vivo proteolysis. 
Using the mobilities of the Tm samples to estimate the apparent molecular weights 
of the carbohydrate-free polypeptides, the approximate weights of parental, $1U9, and 
T7 H  chains were 53,000, 42,000, and 40,000, respectively. The deletions of $1U9 and 
T7  are  thus  of  -95  and  115  amino  acid  residues,  respectively.  For  making  the 
molecular weight estimates, phosphate rather than Tris-glycine gels were used because 
they have been reported to be less susceptible to artifactual errors (38). Taken together 
these studies indicate that variants phenotypically similar to the 47A group of tumors 
can arise spontaneously in culture from myelomas producing normal IgA molecules. 
Constant Region Serology.  Since the 47A protein is known to lack its CH3 domain  (6), 
its  serology  was  compared  with  $1U9,  T7,  and  their  respective  parents.  Double 
diffusion  in agar  (Ouchterlony technique)  was used  to compare the reactivity of all 
these proteins in all possible combinations with a  rabbit antiserum specific for the Fc 
region  of BALB/c  IgA.  There  was  complete  identity  among  $1U9,  T7,  47A,  and 
between  the  two  parental  molecules  (data  not  shown).  In  all  cases  the  parental 
molecules spurred over each of the three variants, indicating that the parental proteins 
contain  Fc-region determinants  not present  in the three  variant  molecules.  This was 
confirmed by absorbing antiserum with $1U9 attached to Sepharose and showing that 1560  MYELOMA VARIANTS SYNTHESIZING IgA HALF-MOLECULES 
the absorbed antiserum did not react in agar diffusion with T7 or 47A, but continued 
to react strongly with S107 and W3082. 
The  serological similarity  of $1U9,  T7,  and  47A  was  further  supported  by their 
reactivities  with  two  rat  anti-IgA  constant  region  antibodies.  Table  I  shows  the 
reactivity  of  the  two  parental  proteins,  their  respective  variants,  and  47A  with 
monoclonals R21  and  R99 as measured by the inhibition  of hemagglutination.  All 
five proteins reacted similarly with R99.  In contrast, the three variant molecules did 
not react with R21, whereas the parental molecules did. Parenthetically, this suggests 
that R21  recognizes antigenic determinants on the CH3 domain of the IgA molecule. 
Carboxypeptidase  Digestion.  The electrophoretic behavior and serological character- 
istics of the variants taken together with the known structure of 47A indicated  that 
SaU9  and  T7  no  longer  contained  some or  all  of the  CH3  domain.  To  determine 
whether this was due to an internal or C-terminal deletion, an attempt was made to 
compare the C-terminal sequence of S107 with $1U9 and of W3082 with T7. Since it 
has been reported that MOPC 511  (another BALB/c IgA myeloma protein) has a C- 
terminal  tyrosine  (29),  the  parental  and  variant  proteins  were  labeled  with 
[3H]tyrosine,  digested  with  carboxypeptidases  A  and  B,  and  the  release  of TCA 
soluble counts was measured. Fig. 3 shows the expected rapid release of tyrosine from 
S107 and W3082, whereas with SxU9 and T7 the release is only at background levels. 
This suggests that the variants do not have the normal C-terminal sequence. However, 
it is also possible that the C-terminal amino acid is protected in the variants due to a 
conformational change.  In order to gain further sequence information, carboxypep- 
tidase digestion of unlabeled,  purified H  chain followed by amino acid analysis was 
attempted.  However,  at  all  time  points  examined  the  yield  was  too  low  and  the 
background too high to provide meaningful results. 
Membrane Association.  It is generally believed, but not  formally proven, that a  C- 
terminal hydrophobic segment in membrane immunoglobulin serves to anchor it in 
the  plasma  membrane.  Since  S107  contains  membrane  immunoglobulin  (39),  the 
presumptive C-terminal deletion of the variant $1U9 made it interesting to determine 
whether the variant possessed membrane immunoglobulin. S 107 and $1U9 cells were 
both  treated  with  cycloheximide  for  3  h  to  void  the  cells  and  membranes  of "in 
transit"-secreted immunoglobulin and then surface-labeled by the 12~I/lactoperoxidase 
method.  The membranes were then solubilized,  immunoprecipitated,  and  analyzed 
TABLE  I 
Constant Region Serology: Hemagglutination Inhibition (HAI) with Two 
Monoclonal Antibodies 
Inhibiting protein 
HAI (log2 titer) 
Hemagglutinating antibody 
R99  R21 
W3082  8.0*  8.5 
T7  8.5  0 
S107  6.5  8.0 
SIU9  8.5  0 
47A  9.5  0 
* Value represents average of determinations don]e in duplicate. In all cases 
the duplicates were no more than one well apart. ZACK,  MORRISON,  COOK,  DACKOWSKI,  AND  SCHARFF  1561 
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FIG.  3.  Carboxypeptidase digestions of S107, SaU,, W3082, and T7 proteins. S107, S]Ua, W3082, 
and T7 proteins were labeled with [aH]tyrosine and digested with a mixture of carboxypeptidases 
A and B for 2.5, 5, 15, 40, and 90 min as described in Materials and Methods. The amount of TCA- 
soluble radioactivity was measured for each time point. Control samples were incubated for 90 min 
with carboxypeptidase that had been boiled for 15 rain in 0.1  M acetic acid. 
Fxc;.  4.  Surface labeling of S107 and SIUa cells. S107  and SIUa cells were surface labeled by the 
a~SI-lactoperoxidase method as described in Materials and Methods. Membranes were solublized in 
NP-40, immune precipitated, and electrophoresed on a 7.5% phosphate gel. Samples are as follows: 
a,  control  [~4C]lysine-labeled  secreted  S107  protein;  b,  1~5I surface-labeled S107;  c,  lz~I surface- 
labeled S]Ug; d, control [14C]lysine-labeled  secreted S]Ua protein. Equal numbers of TCA precipi- 
table counts were added to lanes b and c. 
by  SDS-PAGE.  Although  Fig.  4,  lane  b,  clearly  shows  bands  corresponding  to  S 107 
H  and L, there are no bands  in lane c corresponding  to S]Ua H  and L. For comparison, 
lane  d  shows  the  positions  of  secreted  S]Us  H  and  L.  The  greater  intensity  of 
contaminating  bands  in lane c  relative to lane b  is due to the fact that equal numbers 1562  MYELOMA VARIANTS SYNTHESIZING IgA HALF-MOLECULES 
of counts were loaded in both lanes, although lane c contained no H  or L. When the 
cells were not pretreated with cycloheximide, clear bands corresponding to $1U9 H 
and  L were seen, indicating that  it is possible to iodine label the in transit-secreted 
immunoglobulin passing through the plasma membrane (data not shown). A similar 
experiment with T7 was not possible because attempts at surface labeling W3082 and 
T7 yielded little, if any, labeling of membrane immunoglobulin, presumably because 
of its absence or the inacessibility of its tyrosine residues. 
Analysis of DNA and mRNA.  It is possible to distinguish between DNA deletions, 
processing defects leading to mRNA deletions, and premature terminations by directly 
examining the sizes of the constant region genes and mRNA coding for the IgA H 
chains. When the parental and variant DNA were compared by restriction analysis 
no differences were detected. Fig. 5 shows genomic Southern blots of Eco R 1 and Msp 
I  fragments  of the  parental  and  variant  cell  lines  probed  with  an  Eco R1-Sma  I 
fragment containing half of the Cn2 and all of the CH3 constant region domains. In 
all four cell lines, the probe hybridizes to a single 4.4 kb Eco R 1 fragment (lanes a-d) 
and a single 2.3 kb Msp I fragment (lanes e-h). 
Fig. 6 shows a Northern blot of the cytoplasmic mRNA probed with the same nick- 
translated  Eco R1-Sma I  fragment. The sizes  of the IgA heavy chain mRNA were 
identical in all four cell lines. It should be noted that using this same system one of us 
was  able  to  clearly detect  a  size  difference in  the  mRNA  that  coded  for an  IgA 
molecule with a partially deleted Cnl domain (Sherie Morrison, unpublished results). 
These results taken together with the carboxypeptidase experiment and the electro- 
phoretic behavior of the variants indicate that  the short heavy chains do not result 
either from the deletion of the gene or from a splicing defect. 
Variable Region Serology.  It was important to determine whether the variants contain 
the same variable region as the parental  proteins. This could be done serologically 
with S107 and S~U9 because S107 bears the well-defined T-15 idiotype, the predom- 
inant idiotype expressed in BALB/c mice immunized with PC (40, 41). The idiotype 
of S~U9 was examined by comparing its reactivity to that  of S107 with a  panel of 
seven monoclonal anti-T-15 antibodies, which have been shown to react with at least 
six  independent  idiotopes  (Angela  Giusti  and  Catherine  Desaymard,  unpublished 
results). S 107 and $1U9 inhibited the hemagglutination of S 107-coated SRBC by each 
of the  monoclonals  to  the  same  relative  degree.  The  reactivity  of one  of these 
monoclonals (R  101) with both S107 and $1U9 was also the same when measured by 
the more sensitive technique of RIA (data not shown). 
Rabbit antibodies specific for the hapten-binding site of S 107 were prepared by the 
method  of Claflin  and  Davie  (23).  This  antibody  was  attached  to  the  wells  of a 
polyvinyl microtiter plate, and the ability of S107 and  $1U9 proteins to inhibit  the 
binding  of [aSS]methionine-labeled  S107  was  compared.  Within  the  error  of the 
method, the two inhibition curves are identical (Fig.  7). These results indicated that 
S107 and $1U9 contain the same variable region and suggest that the formation of the 
inter H-L chain disulfide bond does not cause major changes in the conformation of 
the hapten-binding site nor in at least some other sites of the variable region. 
Affinity of Sl07 and SaUgfor Hapten.  Although  S107  protein is easily purified by 
affinity chromatography, initial attempts at purification of $1U9 protein yielded very 
little bound material. Analysis of the protein content of the pre-PC  (wash)  fractions 
revealed two peaks  of 280  nm  absorbing material.  The second peak  (peak II)  was ZACK, MORRISON,  COOK,  DACKOWSKI, AND  SCHARFF  1563 
FIG. 5.  Southern  blot hybridization of S107, SxUg, W3082, and T7  genomic  DNA.  DNA was 
~repared,  restricted, electrophoresed, and hybridized as described in Materials and Methods. The 
Z~p nick-translated probe used was the 1.6 kb Eco R 1-Sma I alpha gene fragment that contains half 
of CH2 and all of CH3. The DNA in lanes a-d and e-h was restricted with  Eco R1  and Msp I, 
respectively. Samples are as follows: a and e, S107; b and f, $1U9; e and g, T7; c and d, W3082. 
enriched for serologically detectable SaU9 protein. SDS-PAGE showed that  the peak 
II  material  was  only  partially purified.  However,  when  the  peak  II  material  was 
passed over the PC-column a  second time, it eluted as before but did not contain any 
contaminating proteins by SDS-PAGE. 
In order to further evaluate this apparent  difference in binding between $1U9 and 
S107,  the affinity of the parent  and  variant  for PC  was measured  using the steady- 
state method of equilibrium dialysis (24).  Fig. 8  shows the results for $1U9  plotted in 
the  form  of a  Scatchard  analysis.  The  plot,  drawn  according  to  the  least  squares 
analysis (with a  correlation coefficient of-0.991),  yields an association constant  (Ka) 
of 2.23 X  105 M -a. The number of binding sites per molecule is calculated to be  1.09. 1564  MYELOMA  VARIANTS  SYNTHESIZING  IgA  HALF-MOLECULES 
F[o.  6.  Northern blot hybridization of Sl07, $1U9, W3082, and T7 cytoplasmic RNA. Cytoplasmic 
RNA was prepared, electrophoresed, and hybridized as described in Materials and Methods. The 
probe  used was the same as  that  for  Fig.  5.  Samples are as follows:  a,  S107;  b,  $1U9;  c,  T7;  d, 
W3082. 
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FIc.  7.  RIA comparison of the reactivity of S107 and $1U9 protein with a rabbit anti-PC binding 
site-specific antibody. Binding site-specific antibody was prepared and used in an RIA as described 
in  Materials and Methods.  PC-KLH was attached to  polyvinyl plates and a  constant amount of 
[~S]S107 was added to each well. Increasing amounts of purified S107 or $1U9 protein were added 
as cold inhibitors. 
A  Sips plot of the same data  (not shown)  gives a  homogeneity index of 0.992 where 
1.0 would indicate a  totally homogeneous population.  Using the same methodology 
we obtained a  Ka of 2.20  X  10  ~ M -a for the parental  S107  molecule. The difference 
between the parent and variant Ka is certainly within the error of the method, and we 
conclude that  they have the same affinity for the hapten.  Because StU9  protein has ZACK, MORRISON,  COOK,  DACKOWSKI, AND SCHARFF 
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Discussion 
The  results  presented  above  demonstrate  that  cultured  mouse  myeloma  ceils 
producing normal IgA antibody can spontaneously give rise to variants that produce 
IgA half-molecules containing H  chains lacking all or part of their Crt3 domain. These 
variant proteins closely resemble those produced by a  series of BALB/c tumors first 
described in 1964 by Potter and Kuff (4). It is not possible at this time to estimate the 
exact rate at which such variants arise. The two variants described in this paper were 
identified  during  experiments  designed  to  detect  other  phenotypes  that  arise with 
frequencies of 0.1-1%. Since only one half-molecule producer apiece has been isolated 
from S107 and W3082 so far, their frequency could be quite low. A large number of 
somatic variants with constant region deletions or premature terminations have been 
isolated from a  variety of IgG- and IgM-producing mouse myeloma and hybridoma 
cell lines and their frequency varies enormously (9, 43-45). 
Both $1U9 and T7 have the unusual covalent structure of 47A and the other half- 
FIG. 8.  Equilibrium dialysis  of purified S]U9 protein. Equilibrium dialysis  was done by the steady- 
state, flow dialysis method described in Materials and Methods. The data are plotted in the form 
of a Scatchard analysis. 
unaltered affinity for the hapten PC as compared with S 107 protein, the difference in 
their binding to PC-sepharose columns most likely reflects a  difference in avidity-- 
partially  reduced  S107  is  bivalent,  whereas  SxU9  is  monovalent.  With  TEPC  15 
protein  (which  has a  sequence  identical  to that  of $107  protein),  a  similar binding 
difference between the bivalent  H2L2 monomer and  monovalent Fab  fragment has 
been observed (42). 
It is more difficult to compare the affinities of W3082 and its T7 variant for levan. 
T7 was neither bound  to, nor retarded  in elution  from, a  levan-Sepharose column. 
However, when the T7 molecules were made polyvalent by the sequential addition of 
rabbit  anti-IgA  and  sheep  anti-rabbit  immunoglobulin,  binding  of  some  of  the 
molecules was detected (data not shown). This suggests that T7 retains at least some 
capacity to bind antigen. 1566  MYELOMA  VARIANTS SYNTHESIZING IgA HALF-MOLECULES 
molecule-producing tumors.  Based on a  comparison of the amino acid sequences of 
47A and MOPC 511  (511), a  PC-binding IgA myeloma, Robinson and Appella (29) 
concluded  that  the  formation of inter-H-L disulfide  bonds  and  absence of inter-H 
chain disulfide bonds were due solely to the deletion of the Cn3  domain.  Assuming 
that  this  is also true of $1U9,  it would  mean  that  even a  partial  deletion  of the  C- 
terminal domain can have a  long-range affect on the folding and covalent structure 
of the hinge and CH 1 domain.  Since x-ray crystallography has shown,  at least for a 
human Fc fragment (46), that there is essentially no CH2-CH2 contact though there is 
significant  CH3-CH3 contact,  the  half-molecule phenotype may be due  to  a  loss  of 
CH3-CH3 stabilizing interactions that might be necessary in an IgA molecule to form 
inter-H  chain  disulfide  bonds.  The resulting  lack of interchain  bonds  might  make 
cysteines available to participate in the formation of an abnormal H-L bond. Such a 
finding indicates that the domains can affect each other, as has been postulated in the 
initiation of effector functions such as complement fixation and Fc receptor binding 
(47).  On the other hand,  the formation of the disulfide bond between  the H  and L 
chains did not affect the serology or affinity of the $1U9 variable region. 
Since the proteins of $107 and its variant $1U9 both bind the hapten PC with the 
same affinity and both bear the T-15 idiotype, they almost certainly have the same H 
chain variable region. As T7 still reacts with levan, it is probable that W3082 and its 
variant also express the same variable region. The identity of constant genes between 
parents and variants presents a potentially more difficult question. Although unlikely, 
it is possible that the H  chain deletions are not due to somatic mutation but rather to 
a  class switch to a  rarely expressed alpha subclass or even to a  pseudogene. Arguing 
against such a subclass switch or germ-line pseudogene is the difference in size between 
the $1U9 and T7 H chains and the restriction map identity of the parents and variants. 
Furthermore, although S 107 and W3082 both contain at least three alpha genes (our 
"unpublished  results),  none  is  in  the  germ-line configuration.  Thus,  a  switch  would 
have to involve rearrangement to an already rearranged gene, an event which has not 
been observed. 
On  the basis of the 47A  and  511  sequence  comparison and  the  finding  that  the 
mRNA coding for 47A was of normal size, it was proposed that a single base has been 
deleted  from the codon  for valine 336,  resulting  in  the generation  of a  termination 
codon (29,  48). From the apparent molecular weights of the Tin-treated samples, the 
$1U9 H  chain lacks ~ 11,000  dahons or 95 amino acids, whereas while the T7 H  chain 
has  lost  13,000  daltons  or  115  amino acids.  Both  $1U9  and T7  lack CH3  antigenic 
determinants and do not appear to have the parental C-terminal tyrosine. The size 
difference between the variant H chains is not the result of proteolysis or glycosylation 
differences because similarly short H  chains were synthesized in a cell-free system and 
by Tin-treated cells. The cytoplasmic mRNA from both variants were the same size 
as parental messenger. These findings suggest that both variants also arise through a 
premature termination,  either due to a  nonsense or frameshift mutation.  However, 
detailed  sequence analysis will be required  to prove such  a  mechanism.  It  is worth 
noting that  two of the four IgG variants described by Adetugbo and his colleagues 
(43, 49) arose through premature terminations and that the M311  variant of MPC  11 
probably has a similar origin (50). 
The appearance of a number of IgA-producing mouse myeloma tumors with similar 
phenotypes might suggest a  hot spot (29).  It is interesting that 47A and T7 have the ZACK, MORRISON, COOK, DACKOWSKI,  AND SCHARFF  1567 
same mobility on SDS gels.  However, SxU9 has a  smaller  deletion,  indicating that 
mutations can occur within  the Cn3  domain as well  as at  the Cn2-Cn3 boundary. 
Furthermore, rather than reflecting a  localized mutagenic process, the occurrence of 
relative hot spots for deletion may simply be the result of areas of nucleotide sequence 
that are easily altered into termination signals, or may reflect unrealized biases in the 
selection  techniques  utilized  or  restrictions  arising  from  the  need  to  maintain  cell 
viability. 
Summary 
Whereas mouse myelomas that secrete IgA half-molecules have been shown to arise 
in vivo, their origin has not been definitely established. We show that somatic variants 
secreting phenotypically similar  molecules can arise  directly from the  normal  IgA- 
secreting myelomas S107 and W3082. In addition to being improperly assembled, the 
variant proteins have distinct carboxy-terminal deletions and an aberrant heavy-light 
chain disulfide bond.  For at  least  one of the variants,  variable region serology and 
affinity for hapten are both unaffected by these changes. Southern and Northern blot 
analyses  indicate  normal  size  DNA  restriction  fragments  and  mRNA,  suggesting 
premature termination as the mechanism of deletion. These results are discussed in 
relation to possible mutational hot spots and long-range interdomain interactions. 
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assistance; Amy Kenter,  Dr. Barbara Birshtein, and Richard Campbell  for useful discussions 
and their help with our attempts at cold carboxypeptidase  sequencing; Dr. Fred Mushinski for 
his generous gift of purified 47A protein;  and Dr. Phil Tucker for providing  us with his alpha 
heavy chain nucleic acid sequence before publication. 
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